Skip to main content

Advertisement

SpringerLink
Log in

Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ursaru M, Jari I, Naum A, Scripcariu V, Negru D. Causes of death in patients with stage 0-II breast cancer. Rev Med Chir Soc Med Nat Iasi. 2015;119(2):374–8.

    PubMed  Google Scholar 

  2. Maltoni R, Gallerani G, Fici P, Rocca A, Fabbri F. CTCs in early breast cancer: a path worth taking. Cancer Lett. 2016;376(2):205–10. https://doi.org/10.1016/j.canlet.2016.03.051.

    Article  CAS  PubMed  Google Scholar 

  3. Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor dna as liquid biopsy. Cancer Discov. 2016;6(5):479–91. https://doi.org/10.1158/2159-8290.CD-15-1483.

    Article  CAS  PubMed  Google Scholar 

  4. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10(20):6897–904. https://doi.org/10.1158/1078-0432.CCR-04-0378.

    Article  PubMed  Google Scholar 

  5. Xu L, Jia S, Li H, Yu Y, Liu G, Wu Y, et al. Characterization of circulating tumor cells in newly diagnosed breast cancer. Oncol Lett. 2018;15(2):2522–8. https://doi.org/10.3892/ol.2017.7540.

    Article  CAS  PubMed  Google Scholar 

  6. Martin M, Garcia-Saenz JA, Maestro De las Casas ML, Vidaurreta M, Puente J, Veganzones S. Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis. Anticancer Res. 2009;29(10):4185–7.

    PubMed  Google Scholar 

  7. Banys-Paluchowski M, Krawczyk N, Fehm T. Potential role of circulating tumor cell detection and monitoring in breast cancer: a review of current evidence. Front Oncol. 2016;6:255. https://doi.org/10.3389/fonc.2016.00255.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Franken B, de Groot MR, Mastboom WJ, Vermes I, van der Palen J, Tibbe AG, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012;14(5):R133. https://doi.org/10.1186/bcr3333.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91. https://doi.org/10.1056/NEJMoa040766.

    Article  CAS  PubMed  Google Scholar 

  10. Harouaka R, Nisuc M, Zheng S. Circulating tumor cell enrichment based on physical properties. J Lab Autom. 2013;18(6):10. https://doi.org/10.1177/2211068213494391.

    Article  CAS  PubMed Central  Google Scholar 

  11. Ferreira MM, Ramani VC, Jeffrey SS. Circulating tumor cell technologies. Mol Oncol. 2016;10(3):374–94. https://doi.org/10.1016/j.molonc.2016.01.007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ohnaga T, Shimada Y, Takata K, Obata T, Okumura T, Nagata T, et al. Capture of esophageal and breast cancer cells with polymeric microfluidic devices for CTC isolation. Mol Clin Oncol. 2016;4(4):599–602. https://doi.org/10.3892/mco.2016.734.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lustberg MB, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, et al. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Res. 2014;16(2):R23. https://doi.org/10.1186/bcr3622.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer. 2010;10:666. https://doi.org/10.1186/1471-2407-10-666.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–96. https://doi.org/10.1038/nrm3758.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Imani S, Hosseinifard H, Cheng J, Wei C, Fu J. Prognostic value of emt-inducing transcription factors (emt-tfs) in metastatic breast cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:28587. https://doi.org/10.1038/srep28587.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Liu F, Gu L, Shan B, Geng C, Sang M. Biomarkers for EMT and MET in breast cancer: an update. Oncol Lett. 2016;12(6):4869–76. https://doi.org/10.3892/ol.2016.5369.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lima J, Nofech-Mozes S, Bayani J, Bartlett J. EMT in breast carcinoma—a review. J Clin Med. 2016;5(7):65. https://doi.org/10.3390/jcm5070065.

    Article  CAS  Google Scholar 

  19. Fu M, Maresh EL, Helguera GF, Kiyohara M, Qin Y, Ashki N, et al. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther. 2014;13(4):902–15. https://doi.org/10.1158/1535-7163.MCT-13-0199.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kiyohara MH, Dillard C, Tsui J, Kim SR, Lu J, Sachdev D, et al. EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene. 2017;36(42):5793–807. https://doi.org/10.1038/onc.2017.142.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67. https://doi.org/10.1016/j.stem.2007.08.014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Schneck H, Gierke B, Uppenkamp F, Behrens B, Niederacher D, Stoecklein NH, et al. EpCAM-independent enrichment of circulating tumor cells in metastatic breast cancer. PLoS One. 2015;10(12):e0144535. https://doi.org/10.1371/journal.pone.0144535.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Gostner JM, Fong D, Wrulich OA, Lehne F, Zitt M, Hermann M, et al. Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer. 2011;11:45. https://doi.org/10.1186/1471-2407-11-45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med (Lausanne). 2017;4:227. https://doi.org/10.3389/fmed.2017.00227.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet. 2000;356(9246):1981–2. https://doi.org/10.1016/S0140-6736(00)03312-2.

    Article  CAS  PubMed  Google Scholar 

  26. Hyun KA, Koo GB, Han H, Sohn J, Choi W, Kim SI, et al. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget. 2016;7(17):24677–87. https://doi.org/10.18632/oncotarget.8250.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Sankpal NV, Fleming TP, Sharma PK, Wiedner HJ, Gillanders WE. A double-negative feedback loop between EpCAM and ERK contributes to the regulation of epithelial-mesenchymal transition in cancer. Oncogene. 2017;36(26):3706–17. https://doi.org/10.1038/onc.2016.504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Sheng Y, Wang T, Li H, Zhang Z, Chen J, He C, et al. Comparison of analytic performances of Cellsearch and iFISH approach in detecting circulating tumor cells. Oncotarget. 2017;8(5):8801–6. https://doi.org/10.18632/oncotarget.6688.

    Article  PubMed  Google Scholar 

  29. Bulfoni M, Turetta M, Del Ben F, Di Loreto C, Beltrami AP, Cesselli D. Dissecting the heterogeneity of circulating tumor cells in metastatic breast cancer: going far beyond the needle in the haystack. Int J Mol Sci. 2016;17(10):1710–75. https://doi.org/10.3390/ijms.

    Article  Google Scholar 

  30. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009;11(4):R46. https://doi.org/10.1186/bcr2333.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Tsui J, Ashki N, Chang Y, Patel D, Sjarif J, Wadehra M. Epithelial membrane protein 2 is a novel regulator of immune editing in breast cancer. Cancer Res. 2017;77(13):3965.

    Article  Google Scholar 

  32. Gross HJ, Verwer B, Houck D, Hoffman RA, Recktenwald D. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(−7). Proc Natl Acad Sci USA. 1995;92(2):537–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Beitsch PD, Clifford E. Detection of carcinoma cells in the blood of breast cancer patients. Am J Surg. 2000;180(6):446–8 (discussion 8-9).

    Article  CAS  PubMed  Google Scholar 

  34. Hawes D, Neville AM, Cote RJ. Detection of occult metastasis in patients with breast cancer. Semin Surg Oncol. 2001;20(4):312–8.

    Article  CAS  PubMed  Google Scholar 

  35. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010;288(1):99–106. https://doi.org/10.1016/j.canlet.2009.06.027.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Dr. Shengwen Shao at the Institute of Microbiology and Immunology, Huzhou University School of Medicine for his professional help on cell-staining and images taking.

Author information

Author notes

  1. Q. Chen and L. Yao contributed equally to this work.

Authors and Affiliations

  1. Key Laboratory for Translational Medicine and the Division of Breast Surgery, The First Affiliated Hospital of Huzhou University School of Medicine, Huzhou, 313000, Zhejiang, China

    Q. Chen & L. Yao

  2. Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA

    D. Burner, B. Minev & W. Ma

  3. Calidi Biotherapeutics, San Diego, CA, 92121, USA

    B. Minev

  4. Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale School of Medicine, Yale Cancer Center, New Haven, CT, 06520, USA

    L. Lu

  5. Division of Gastrointestinal SurgeryThe First Affiliated Hospital and the Department of Clinical Medicine, Jiaxing University School of Medicine, Jiaxing, 314001, Zhejiang, China

    M. Wang

Authors
  1. Q. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Burner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Minev
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to M. Wang or W. Ma.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical statement

This study was reviewed and approved by the ethics committee of the institutional review board (IRB, HU2014-04), the First Hospital Affiliated to Huzhou University School of Medicine. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee.

Informed consent

Informed consent forms were obtained from all individual participants who were included in the study.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 114 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, Q., Yao, L., Burner, D. et al. Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer. Clin Transl Oncol 21, 433–442 (2019). https://doi.org/10.1007/s12094-018-1941-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-018-1941-1

Search

Navigation